Overview

Toripalimab Combined With SBRT for NSCLC

Status:
NOT_YET_RECRUITING

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

This study aimed to evaluate the efficacy and safety of Toripalimab injection (js001) combined with SBRT radiotherapy and neoadjuvant therapy with or without chemotherapy for operable or potentially operable stage IIa to IIIb NSCLC

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Pulmonary Hospital, Shanghai, China

Treatments:

toripalimab